Zilovertamab Vedotin in Mantle Cell Lymphoma: Promising Results from ASH 2024
New data on the treatment of mantle cell lymphoma (MCL) with zilovertamab vedotin were unveiled at ASH 2024. Zilovertamab vedotin targets ROR1, a novel therapeutic target in MCL, offering a new approach for this challenging malignancy. Professor Ingrid Glimelius, an oncologist at Uppsala University, Sweden, contributed to the study. In a MEDtalk, she shares her insights into these findings, discussing the clinical implications and future perspectives for ROR1-directed therapies in hematologic oncology.
